XML 24 R11.htm IDEA: XBRL DOCUMENT
v3.23.3

REVENUES | 9 Months Ended
--- | ---
Sep. 30, 2023
REVENUES |
REVENUES | NOTE 4 – REVENUES ​ The following table summarizes the Company’s disaggregation of revenues: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
(U.S. dollars in thousands) |  | 2023 |  | 2022 | ​ | 2023 |  | 2022 | ​
Pfizer | ​ | $ | 2,304 | ​ | $ | 4,541 | ​ | $ | 7,972 | ​ | $ | 11,279 | ​
Brazil | ​ | $ | 2,320 | ​ | $ | 1,708 | ​ | $ | 5,120 | ​ | $ | 7,162 | ​
Chiesi | ​ | $ | 5,544 | ​ | $ | 2,563 | ​ | $ | 17,217 | ​ | $ | 2,781 | ​
Total revenues from selling goods | ​ | $ | 10,168 | ​ | $ | 8,812 | ​ | $ | 30,309 | ​ | $ | 21,222 | ​
Revenues from license and R&D services | ​ | $ | 177 | ​ | $ | 5,371 | ​ | $ | 24,699 | ​ | $ | 17,799 | ​
​

X
- Definition The entire disclosure pertaining to revenue. + References No definition available. + Details
Name: | plx_RevenueDisclosureTextBlock
Namespace Prefix: | plx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration